GGI
ALNY icon

Godsey & Gibb Inc’s Alnylam Pharmaceuticals ALNY Stock Holding History

Godsey & Gibb Inc’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.63K Hold
32
– – ﹤0.01% 278
2026
Q1 		$10.6K Hold
32
– – ﹤0.01% 277
2025
Q4 		$12.7K Buy
32
+4
+14% +$1.77K ﹤0.01% 278
2025
Q3 		$12.8K Buy
+28
New +$11.4K ﹤0.01% 250

Other funds holding ALNY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Godsey & Gibb Inc's ALNY Position: Q2 2026 in Review

Godsey & Gibb Inc held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 32 shares worth $9.63K. The position accounts for ﹤0.01% of the portfolio, ranked #278.

Godsey & Gibb Inc first reported a position in ALNY in Q3 2025 and has held it in 4 quarters since. The position peaked at $12.8K in Q3 2025. 365 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Godsey & Gibb Inc held 32 shares of Alnylam Pharmaceuticals worth $9.63K as of Q2 2026.
  • Godsey & Gibb Inc left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Godsey & Gibb Inc's portfolio in Q2 2026, its #278 holding.
  • Godsey & Gibb Inc first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Godsey & Gibb Inc's Alnylam Pharmaceuticals position peaked at $12.8K in Q3 2025.
  • 365 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Godsey & Gibb Inc's 13F filing for Q2 2026, filed 13 Jul 2026.